Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 4/20 | 0.75 |
| ▸ | THRA | P10827 | 3/20 | 0.75 |
| ▸ | RORC | P51449 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7094647 | 0.91 | THRB (0.61) | THRBTHRARORC | |
| SCHEMBL8799875 | 0.90 | THRB (0.60) | THRBTHRARORC | |
| SCHEMBL281877 | 0.86 | THRA (1.00) | THRBTHRA | |
| SCHEMBL29373673 | 0.86 | THRA (1.00) | THRBTHRA | |
| SCHEMBL7584863 | 0.85 | THRB (0.57) | THRBTHRARORC | |
| SCHEMBL8892202 | 0.85 | THRB (0.54) | THRBTHRARORC | |
| SCHEMBL8798523 | 0.84 | THRB (0.54) | THRBTHRARORC | |
| SCHEMBL282165 | 0.82 | THRB (0.53) | THRBTHRARORC | |
| SCHEMBL8800898 | 0.81 | THRB (0.51) | THRBTHRARORC | |
| SCHEMBL282237 | 0.81 | THRB (0.51) | THRBTHRARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166731-A1 | Method of treating hair loss using diphenylether derivatives | THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER | 2003-09-04 | — | — | US | disclosed |
| US-6525094-B1 | Topical application of compound that interacts strongly with thyroid hormone receptors but sparingly with heart selective hormone receptors | THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER | 2003-02-25 | — | — | US | disclosed |
| EP-0580550-B1 | Oxamic acid derivatives as hypocholesteremic agents | CIBA GEIGY AG (CH) | 1997-10-22 | — | — | EP | disclosed |
| US-5654468-A | ANTILIPID, ANTICHOLESTEROL AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5569674-A | ANTICHOLESTEROL AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-10-29 | — | — | US | disclosed |
| US-5401772-A | Anticholesterol agents with aromatic amines | CIBA-GEIGY CORPORATION (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0580550-A1 | Oxamic acid derivatives as hypocholesteremic agents | CIBA-GEIGY AG (CH) | 1994-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166731-A1 | Method of treating hair loss using diphenylether derivatives | CYP27A1, DHCR7, CYP11A1 | THRB 716/4885THRA 1397/4885RORC 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.